Large shareholder sells some Orphazyme shares shortly before vital FDA ruling, general partner denies connection

As the FDA's response deadline for Orphazyme's drug candidate arimoclomol draws ever closer, Sunstone Life Science Ventures has opted to sell some of its shares in the biotech company.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app